Final report of University Hospital Hradec Kralove to the clinical trial protocol no. BAY 86-5321/16598
Abstract
An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of 2 mg aflibercept administered by intravitreal injections using two different treatment regimens to subjects with neovascular age-related macular degeneration (nAMD). (AZURE, Protocol BAY 86-5321 / 16598)